Molecular genetics of gastroenteropancreatic neuroendocrine tumors

Current Opinion in Oncology

Volumn 21, Issue 1, 2009, Pages 29-33

  Starker, Lee F ^a   Carling, Tobias ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoid; Endocrine; Genetic; Molecular; Pancreas; Tumor

Indexed keywords

VON HIPPEL LINDAU PROTEIN;

CANCER DIAGNOSIS; CANCER INCIDENCE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GENE; GENE MUTATION; HEALTH; HUMAN; MOLECULAR GENETICS; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA GENE; NEUROENDOCRINE TUMOR; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBEROUS SCLEROSIS; VON HIPPEL LINDAU DISEASE; VON HIPPEL LINDAU GENE;

GASTROINTESTINAL NEOPLASMS; GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR BIOLOGY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

EID: 58149239794     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328319ea7b     Document Type: Review

References (58)

1. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9:61-72.
2. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005; 19:753-781.
3. Carling T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol 2005; 17:7-12.
4. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658-5671.
5. Chandrasekharappa S, Guru S, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 1997; 276:404-407.
6. The European Consortium, et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Hum Mol Genet 1997; 6:1177-1183.
7. Carling T, Correa P, Hessman O, et al. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. J Clin Endocrinol Metab 1998; 83:2960-2963.
8. Farnebo F, Teh B-T, Kytölä S, et al. Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab 1998; 83:2627-2630.
9. Heppner C, Kester MB, Agarwal SK, et al. Somatic mutations of the MEN1 gene in parathyroid tumours. Nat Genet 1997; 16:375-378.
10. Hessman O, Lindberg D, Einarsson A, et al. Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN 1 -associated pancreatic endocrine tumors. Genes Chromosomes Cancer 1999; 26:258-264.
11. Hessman O, Lindberg D, Skogseid B, et al. Mutation of the multiple endocrine neoplasia type 1 gene in nonfamilial, malignant tumors of the endocrine pancreas. Cancer Res 1998; 58:377-379.
12. Hessman O, Skogseid B, Westin G, Akerstrom G. Multiple allelic deletions and intratumoral genetic heterogeneity in men1 pancreatic tumors. J Clin Endocrinol Metab 2001; 86:1355-1361.
13. Agarwal SK, Lee Burns A, Sukhodolets KE, et al. Molecular pathology of the MEN1 gene. Ann N Y Acad Sci 2004; 1014:189-198.
14. Agarwal S, Guru S, Heppner C, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999; 96:143-152.
15. Busygina V, Suphapeetiporn K, Marek LR, et al. Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. Hum Mol Genet 2004; 13:2399-2408.
16. Jin S, Mao H, Schnepp RW, et al. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res 2003; 63:4204-4210.
17. Kim H, Lee JE, Cho EJ, et al. Menin, a tumor suppressor, represses JunD- mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res 2003; 63:6135-6139.
18. Schnepp RW, Hou Z, Wang H, et al. Functional interaction between tumor suppressor menin and activator of S-phase kinase. Cancer Res 2004; 64:6791-6796.
19. Schnepp RW, Mao H, Sykes SM, et al. Menin induces apoptosis in murine embryonic fibroblasts. J Biol Chem 2004; 279:10685-10691.
20. Sowa H, Kaji H, Hendy GN, et al. Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2. J Biol Chem 2004; 279:40267-40275.
21. Sowa H, Kaji H, Kitazawa R, et al. Menin inactivation leads to loss of transforming growth factor beta inhibition of parathyroid cell proliferation and parathyroid hormone secretion. Cancer Res 2004; 64:2222-2228.
22. Stalberg P, Grimfjard P, Santesson M, et al. Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J Clin Endocrinol Metab 2004; 89:2326-2337.
23. Hughes CM, Rozenblatt-Rosen O, Milne TA, et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell 2004; 13:587-597.
24. La P, Silva AC, Hou Z, et al. Direct binding of DNA by tumor suppressor menin. J Biol Chem 2004; 19:49045-49054.
25. Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on • cancer-associated target genes. Cancer Cell 2008; 14:36-46. This elegant study further establishes the dual role of menin as a suppressor in endocrine tumorigenesis and as an essential oncogenic cofactor in leukemic transformation.
26. Yaguchi H, Ohkura N, Takahashi M, et al. Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Mol Cell Biol 2004; 24:6569-6580.
27. Bertolino P, Tong WM, Galendo D, et al. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol Endocrinol 2003; 17:1880-1892.
28. Biondi CA, Gartside MG, Waring P, et al. Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol Cell Biol 2004; 24:3125-3131.
29. Crabtree JS, Scacheri PC, Ward JM, et al. Of mice and MEN1: insulinomas in a conditional mouse knockout. Mol Cell Biol 2003; 23:6075-6085.
30. Scacheri PC, Kennedy AL, Chin K, et al. Pancreatic insulinomas in multiple endocrine neoplasia, type I knockout mice can develop in the absence of chromosome instability or microsatellite instability. Cancer Res 2004; 64:7039-7044.
31. Perren A, Anlauf M, Henopp T, et al. Multiple endocrine neoplasia type 1 • (MEN1):lossofoneMEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab 2007;92:1118-1128. This study identified allelic loss at the MEN1 gene locus in small microadenomas and monohormonal endocrine cell clusters in the pancreas of patients with MEN1. suggesting that such genetic abnormalities are early events and contribute to the development of the classic occurrence of multiple small endocrine pancreatic tumors in these patients.
32. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet 2003;361:2059-2067.
33. Corcos O, Couvelard A, Giraud S, et al. Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological, and genetic features. Pancreas 2008; 37:85-93.
34. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317-1320.
35. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2:673-682.
36. Lott ST, Chandler DS, Curley SA, et al. High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis. Cancer Res 2002; 62:1952-1955.
37. Eledrisi MS, Stuart CA, Alshanti M. Insulinoma in a patient with tuberous sclerosis: is there an association? Endocr Pract 2002; 8:109-112.
38. Garbrecht N, Anlauf M, Schmitt A, et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 2008; 15:229-241.
39. Johannessen CM, Reczek EE, James MF, et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 2005; 102:8573-8578.
40. Rachdi L, Balcazar N, Osorio-Duque F, et al. Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1 -dependent manner. Proc Natl Acad Sci U S A 2008; 105:9250-9255.
41. Duerr EM, Mizukami Y, Ng A, et al. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer 2008; 15:243-256.
42. Lindberg D, Akerstrom G, Westin G. Mutational analyses of WNT7A and HDAC11 as candidate tumour suppressor genes in sporadic malignant pancreatic endocrine tumours. Clin Endocrinol (Oxf) 2007; 66:110-114.
43. Wang EH, Ebrahimi SA, Wu AY, et al. Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res 1998; 58:4417-4420.
44. Zhuang Z, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997;57:4682-4686.
45. Chung D, Smith A, Louis D, et al. A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J Clin Invest 1997; 100:404-410.
46. Bartsch D, Hahn SA, Danichevski KD, et al. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene 1999; 18:2367-2371.
47. Toumpanakis CG, Caplin ME. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Am J Gastroenterol 2008; 103:729-732.
48. Maitra A, Hansel DE, Argani P, et al. Global expression analysis of well differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res 2003; 9:5988-5995.
49. Hansel DE, Rahman A, House M, et al. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well differentiated pancreatic endocrine neoplasms. Clin Cancer Res 2004; 10:6152-6158.
50. Kulke MH, Freed E, Chiang DY, et al. High-resolution analysis of genetic • alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer 2008; 47:591 - 603. Using array CGH, this study provides a basis for further investigation of putative oncogenes and tumor suppressor genes involved in the development of Gl NETs.
51. Kytola S, Hoog A, Nord B, et al. Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol 2001; 158:1803-1808.
52. Lollgen RM, Hessman O, Szabo E, et al. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer 2001; 92:812-815.
53. Terris B, Meddeb M, Marchio A, et al. Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system. Genes Chromosomes Cancer 1998; 22:50-56.
54. Wang GG, Yao JC, Worah S, et al. Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors. Mod Pathol 2005; 18:1079-1087.
55. Zhao J, de Krijger RR, Meier D, et al. Genomic alterations in well differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis. Am J Pathol 2000; 157:1431-1438.
56. Zikusoka MN, Kidd M, Eick G, et al. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005; 104:2292-2309.
57. Sjoblom T. Systematic analyses of the cancer genome: lessons learned from sequencing most of the annotated human protein-coding genes. Curr Opin Oncol 2008; 20:66-71.
58. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-274.